develop pulmonary blood clots; encephalitis; stroke; strokes were the result of VZV (shingles); strokes were the result of VZV (shingles); cognitive issues; This is a spontaneous report received from contactable reporter (Other HCP). The reporter is the patient.  A 74 year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), administered in arm right, administration date 06Feb2021 (Lot number: EL9265) at the age of 74 years as dose 2, single for covid-19 immunization at a hospital. Relevant medical history included: "Diabetes" (unspecified if ongoing); "Penicillin allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Metformin, reaction(s): "Allergy". Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EK9231, Location of injection: Arm Right), administration date: 16Jan2021, when the patient was 74 years old, for Covid-19 Immunization. The following information was reported: CEREBROVASCULAR ACCIDENT (caused and prolonged hospitalization, disability, life threatening) with onset 04Jun2021, outcome "not recovered", described as "stroke"; VARICELLA ZOSTER VIRUS INFECTION (caused and prolonged hospitalization, disability, life threatening), HERPES ZOSTER (caused and prolonged hospitalization, disability, life threatening) all with onset 04Jun2021, outcome "not recovered" and all described as "strokes were the result of VZV (shingles)"; COGNITIVE DISORDER (caused and prolonged hospitalization, disability, life threatening) with onset 04Jun2021, outcome "not recovered", described as "cognitive issues"; PULMONARY THROMBOSIS (caused and prolonged hospitalization, disability, life threatening) with onset Aug2021, outcome "not recovered", described as "develop pulmonary blood clots"; ENCEPHALITIS (caused and prolonged hospitalization, disability, life threatening) with onset Aug2021, outcome "not recovered", described as "encephalitis". The patient was hospitalized and prolonged hospitalization for cerebrovascular accident, varicella zoster virus infection, herpes zoster, cognitive disorder, pulmonary thrombosis, encephalitis (hospitalization duration: 119 day(s)). The events "stroke", "strokes were the result of vzv (shingles)", "strokes were the result of vzv (shingles)", "cognitive issues", "develop pulmonary blood clots" and "encephalitis" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (05Nov2021) negative, notes: Nasal Swab Abbott rapid. Therapeutic measures were taken as a result of cerebrovascular accident, varicella zoster virus infection, herpes zoster, cognitive disorder, pulmonary thrombosis, encephalitis which includes acyclovir, immunoglobulins, steroids, anticoagulation and rehabilitation.; Sender's Comments: Based on the information available, a possible contributory role of the suspect BNT162B2 cannot be excluded for the reported events of cerebrovascular accident, varicella zoster virus infection, herpes zoster, cognitive disorder, pulmonary thrombosis, encephalitis  . The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate